TVTX
Travere Therapeutics, Inc. NASDAQ Listed Nov 8, 2012$63.75
-1.53%
vs $64.74
Mkt Cap $5.9B
52w Low $22.05
89.3% of range
52w High $68.73
50d MA $61.50
200d MA $43.61
P/E (TTM)
—
EV/EBITDA
3740.7x
P/B
49.5x
Debt/Equity
2.9x
ROE
-22.2%
P/FCF
150.5x
RSI (14)
41.30
ATR (14)
$2.40
Beta
0.87
50d MA
$61.50
200d MA
$43.61
Avg Volume
1.4M
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of homozygous cystinuria. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy; and TVT-058, a novel investigational human enzyme replacement candidate, which is in Phase I/II clinical trials for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and patient advocacy organizations, CDG Care, and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for NGLY1 deficiency and Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
3611 Valley Centre Drive · San Diego, CA 92130 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 4, 2026 | AMC | -0.13 | -0.37 | -174.8% | 56.02 | +10.7% | +12.0% | -0.5% | -1.8% | -0.7% | -1.1% | — |
| May 4, 2026 | AMC | -0.30 | -0.39 | -30.0% | 44.91 | +1.8% | -0.2% | -0.1% | -4.7% | -0.1% | +2.1% | — |
| Feb 19, 2026 | AMC | 0.03 | 0.03 | +0.0% | 29.30 | +0.6% | +3.7% | +1.1% | +0.5% | -5.0% | +1.3% | — |
| Oct 30, 2025 | AMC | -0.31 | 0.28 | +190.3% | 29.65 | +16.7% | +18.6% | -1.8% | -1.2% | -1.2% | -1.2% | — |
| Aug 6, 2025 | AMC | -0.28 | -0.14 | +50.0% | 17.24 | +1.0% | -1.9% | +0.2% | +2.0% | +0.8% | +3.7% | — |
| May 1, 2025 | AMC | -0.55 | -0.47 | +14.5% | 20.76 | +1.6% | +1.9% | +1.2% | -6.8% | +1.4% | +1.0% | — |
| Feb 20, 2025 | AMC | -0.58 | -0.73 | -25.9% | 23.58 | -8.8% | -6.8% | -3.4% | -2.7% | +1.8% | -1.9% | — |
| Oct 31, 2024 | AMC | -0.70 | -0.70 | +0.0% | 17.50 | +2.6% | +0.4% | +3.0% | -1.9% | -2.5% | +2.1% | — |
| Aug 1, 2024 | AMC | -0.87 | -0.90 | -3.4% | 9.24 | +8.4% | -2.6% | -5.2% | +4.3% | -5.4% | +1.3% | — |
| May 6, 2024 | AMC | -0.98 | -1.76 | -79.6% | 6.55 | +13.0% | +3.1% | +1.0% | -3.2% | -4.5% | +0.6% | — |
| Feb 15, 2024 | AMC | -1.27 | -1.16 | +8.7% | 8.74 | +0.7% | -6.2% | +1.0% | -4.8% | -0.3% | +1.0% | — |
| Nov 7, 2023 | AMC | -1.09 | -1.17 | -7.3% | 7.18 | +0.7% | -11.8% | -14.1% | +2.6% | +2.2% | +6.8% | — |
| Aug 3, 2023 | AMC | -1.16 | -1.13 | +2.6% | 16.28 | -4.0% | -4.7% | -0.8% | +0.7% | -1.6% | +2.8% | — |
| May 4, 2023 | AMC | -1.18 | -1.27 | -7.6% | 15.97 | +0.1% | +5.2% | -0.4% | -1.0% | -1.8% | -0.7% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 24 | Guggenheim | Maintains | Buy → Buy | — | $40.82 | $41.35 | +1.3% | -0.8% | +0.8% | +0.2% | -1.9% | +5.0% |
| Apr 14 | Guggenheim | Maintains | Buy → Buy | — | $30.70 | $41.53 | +35.3% | +37.2% | -2.8% | -3.4% | +3.1% | -1.2% |
| Apr 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $30.70 | $41.53 | +35.3% | +37.2% | -2.8% | -3.4% | +3.1% | -1.2% |
| Apr 14 | Citigroup | Maintains | Buy → Buy | — | $30.70 | $41.53 | +35.3% | +37.2% | -2.8% | -3.4% | +3.1% | -1.2% |
| Apr 14 | Canaccord Genuity | Maintains | Buy → Buy | — | $30.70 | $41.53 | +35.3% | +37.2% | -2.8% | -3.4% | +3.1% | -1.2% |
| Apr 14 | Wedbush | Maintains | Outperform → Outperform | — | $30.70 | $41.53 | +35.3% | +37.2% | -2.8% | -3.4% | +3.1% | -1.2% |
| Mar 25 | JP Morgan | Maintains | Overweight → Overweight | — | $26.79 | $26.84 | +0.2% | +2.9% | +1.3% | -2.4% | +1.5% | +7.4% |
| Feb 6 | Piper Sandler | Maintains | Neutral → Neutral | — | $29.47 | $29.91 | +1.5% | +0.8% | +1.2% | +0.8% | -0.3% | +1.3% |
| Nov 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $36.26 | $36.87 | +1.7% | -2.3% | -0.6% | -3.4% | +2.5% | +1.4% |
| Nov 4 | Piper Sandler | Maintains | Neutral → Neutral | — | $34.53 | $33.99 | -1.6% | -1.2% | -1.2% | -1.2% | -2.9% | +6.3% |
| Oct 31 | TD Cowen | Maintains | Buy → Buy | — | $29.65 | $34.60 | +16.7% | +18.6% | -1.8% | -1.2% | -1.2% | -1.2% |
| Sep 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $24.19 | $24.34 | +0.6% | +2.7% | +2.3% | -4.7% | +0.7% | +0.8% |
| Sep 12 | Stifel | Maintains | Hold → Hold | — | $25.00 | $24.77 | -0.9% | -6.1% | -2.0% | -1.0% | +3.9% | +2.3% |
| Sep 11 | Wells Fargo | Maintains | Overweight → Overweight | — | $27.31 | $27.71 | +1.5% | -8.5% | -6.1% | -2.0% | -1.0% | +3.9% |
| Sep 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $21.64 | $25.31 | +17.0% | +26.2% | -8.5% | -6.1% | -2.0% | -1.0% |
| Sep 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $18.15 | $18.20 | +0.3% | +8.0% | +7.9% | +2.3% | -2.0% | +2.1% |
| Aug 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.44 | $19.30 | +10.7% | +1.5% | -1.1% | +3.7% | +8.0% | +7.9% |
| Aug 7 | Wedbush | Maintains | Outperform → Outperform | — | $17.24 | $17.41 | +1.0% | -1.9% | +0.2% | +2.0% | +0.8% | +3.7% |
| Aug 7 | Scotiabank | Maintains | Sector Outperform → Sector Outperform | — | $17.24 | $17.41 | +1.0% | -1.9% | +0.2% | +2.0% | +0.8% | +3.7% |
| Jun 11 | Citigroup | Maintains | Buy → Buy | — | $15.13 | $15.31 | +1.2% | -4.0% | +2.9% | -2.9% | +1.2% | -4.0% |
| May 16 | Wedbush | Maintains | Outperform → Outperform | — | $21.15 | $18.01 | -14.8% | -20.6% | +1.2% | +3.2% | -5.5% | -5.4% |
| May 2 | Wedbush | Maintains | Outperform → Outperform | — | $20.76 | $21.09 | +1.6% | +1.9% | +1.2% | -6.8% | +1.4% | +1.0% |
| May 2 | Stifel | Maintains | Hold → Hold | — | $20.76 | $21.09 | +1.6% | +1.9% | +1.2% | -6.8% | +1.4% | +1.0% |
| Apr 23 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $15.88 | $16.23 | +2.2% | +5.2% | +5.6% | +4.0% | +5.6% | +3.7% |
| Apr 14 | Guggenheim | Maintains | Buy → Buy | — | $14.50 | $14.95 | +3.1% | +2.3% | +0.5% | -2.3% | +2.4% | +1.3% |
| Apr 10 | Canaccord Genuity | Maintains | Buy → Buy | — | $14.35 | $14.50 | +1.0% | -6.0% | +7.5% | +2.3% | +0.5% | -2.3% |
| Apr 3 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $17.94 | $16.65 | -7.2% | -7.7% | -9.5% | +1.2% | -6.7% | +1.4% |
| Apr 1 | BofA Securities | Maintains | Buy → Buy | — | $17.92 | $18.16 | +1.3% | -2.7% | +2.9% | -7.7% | -9.5% | +1.2% |
| Feb 26 | JP Morgan | Maintains | Overweight → Overweight | — | $20.65 | $21.17 | +2.5% | +1.8% | -1.9% | +3.7% | -7.5% | -0.5% |
| Feb 24 | Citigroup | Maintains | Buy → Buy | — | $21.98 | $22.06 | +0.4% | -3.4% | -2.7% | +1.8% | -1.9% | +3.7% |
| Feb 21 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $23.58 | $21.50 | -8.8% | -6.8% | -3.4% | -2.7% | +1.8% | -1.9% |
| Feb 12 | Scotiabank | Maintains | Sector Outperform → Sector Outperform | — | $23.75 | $23.53 | -0.9% | -2.3% | +2.2% | -3.4% | -1.1% | +3.0% |
| Feb 12 | Canaccord Genuity | Maintains | Buy → Buy | — | $23.75 | $23.53 | -0.9% | -2.3% | +2.2% | -3.4% | -1.1% | +3.0% |
| Feb 12 | Evercore ISI | Maintains | Outperform → Outperform | — | $23.75 | $23.53 | -0.9% | -2.3% | +2.2% | -3.4% | -1.1% | +3.0% |
| Jan 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.07 | $17.54 | +2.8% | +5.9% | +2.2% | -0.5% | +5.9% | +0.0% |
| Nov 14 | Piper Sandler | Maintains | Neutral → Neutral | — | $18.56 | $18.65 | +0.5% | -0.5% | -4.1% | -1.9% | +0.0% | +2.7% |
| Nov 1 | Scotiabank | Maintains | Sector Outperform → Sector Outperform | — | $17.50 | $17.95 | +2.6% | +0.4% | +3.0% | -1.9% | -2.5% | +2.1% |
| Nov 1 | Barclays | Maintains | Overweight → Overweight | — | $17.50 | $17.95 | +2.6% | +0.4% | +3.0% | -1.9% | -2.5% | +2.1% |
| Oct 21 | Wells Fargo | Upgrade | Equal Weight → Overweight | — | $17.87 | $19.12 | +7.0% | +1.3% | -0.7% | -0.1% | +0.7% | -3.1% |
| Oct 11 | Leerink Partners | Maintains | Outperform → Outperform | — | $17.11 | $17.05 | -0.4% | -4.1% | +6.3% | +1.4% | +2.0% | +1.1% |
| Oct 9 | BofA Securities | Maintains | Buy → Buy | — | $15.21 | $15.65 | +2.9% | +15.6% | -2.7% | -4.1% | +6.3% | +1.4% |
| Oct 9 | Wedbush | Maintains | Outperform → Outperform | — | $15.21 | $15.65 | +2.9% | +15.6% | -2.7% | -4.1% | +6.3% | +1.4% |
| Oct 9 | Guggenheim | Maintains | Buy → Buy | — | $15.21 | $15.65 | +2.9% | +15.6% | -2.7% | -4.1% | +6.3% | +1.4% |
| Oct 8 | Leerink Partners | Maintains | Outperform → Outperform | — | $15.26 | $15.31 | +0.3% | -0.3% | +15.6% | -2.7% | -4.1% | +6.3% |
| Oct 1 | Barclays | Maintains | Overweight → Overweight | — | $13.99 | $13.74 | -1.8% | +0.0% | -0.9% | -1.6% | +11.6% | +0.2% |
| Sep 30 | Canaccord Genuity | Maintains | Buy → Buy | — | $14.01 | $14.30 | +2.1% | -0.1% | +0.0% | -0.9% | -1.6% | +11.6% |
| Sep 27 | BofA Securities | Maintains | Buy → Buy | — | $15.04 | $14.18 | -5.7% | -6.8% | -0.1% | +0.0% | -0.9% | -1.6% |
| Sep 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.04 | $14.18 | -5.7% | -6.8% | -0.1% | +0.0% | -0.9% | -1.6% |
| Sep 27 | Guggenheim | Maintains | Buy → Buy | — | $15.04 | $14.18 | -5.7% | -6.8% | -0.1% | +0.0% | -0.9% | -1.6% |
| Sep 27 | Citigroup | Maintains | Buy → Buy | — | $15.04 | $14.18 | -5.7% | -6.8% | -0.1% | +0.0% | -0.9% | -1.6% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Sep 17, 2026 | Dube Eric M | CHIEF EXECUTIVE OFFICER | Sell | 6,802 | $64.95 | $442K | 432,886 | — | — |
| Sep 17, 2026 | Dube Eric M | CHIEF EXECUTIVE OFFICER | Sell | 101,691 | $64.59 | $6.6M | 439,688 | — | — |
| Sep 17, 2026 | Heerma Peter | EVP, CHIEF COMMERCIAL OFFICER | Sell | 8,282 | $65.07 | $539K | 117,066 | — | — |
| Sep 16, 2026 | ROTE WILLIAM E. | Chief Research Officer | Sell | 47,746 | $63.61 | $3.0M | 98,197 | — | — |
| Sep 16, 2026 | ROTE WILLIAM E. | Chief Research Officer | Sell | 65,104 | $63.12 | $4.1M | 145,943 | — | — |
| Sep 16, 2026 | Dube Eric M | CHIEF EXECUTIVE OFFICER | Sell | 96,125 | $63.64 | $6.1M | 432,886 | — | — |
| Sep 16, 2026 | Dube Eric M | CHIEF EXECUTIVE OFFICER | Sell | 99,716 | $63.26 | $6.3M | 529,011 | — | — |
| Sep 16, 2026 | Heerma Peter | EVP, CHIEF COMMERCIAL OFFICER | Sell | 79,113 | $63.65 | $5.0M | 117,066 | — | — |
| Sep 16, 2026 | Heerma Peter | EVP, CHIEF COMMERCIAL OFFICER | Sell | 93,604 | $63.25 | $5.9M | 196,179 | — | — |
| Sep 15, 2026 | REED ELIZABETH E | Chief Legal Officer and GC | Sell | 300 | $65.31 | $20K | 105,389 | — | — |
| Sep 15, 2026 | REED ELIZABETH E | Chief Legal Officer and GC | Sell | 1,400 | $63.69 | $89K | 105,689 | — | — |
| Sep 15, 2026 | REED ELIZABETH E | Chief Legal Officer and GC | Sell | 13,874 | $62.63 | $869K | 107,089 | — | — |
| Sep 15, 2026 | REED ELIZABETH E | Chief Legal Officer and GC | Sell | 21,926 | $62.03 | $1.4M | 120,963 | — | — |
| Sep 15, 2026 | ROTE WILLIAM E. | Chief Research Officer | Sell | 270 | $65.31 | $18K | 98,197 | — | — |
| Sep 15, 2026 | ROTE WILLIAM E. | Chief Research Officer | Sell | 3,000 | $63.65 | $191K | 98,467 | — | — |
| Sep 15, 2026 | ROTE WILLIAM E. | Chief Research Officer | Sell | 29,021 | $62.66 | $1.8M | 101,467 | — | — |
| Sep 15, 2026 | ROTE WILLIAM E. | Chief Research Officer | Sell | 63,907 | $61.99 | $4.0M | 130,488 | — | — |
| Sep 15, 2026 | Dube Eric M | CHIEF EXECUTIVE OFFICER | Sell | 270 | $65.31 | $18K | 432,886 | — | — |
| Sep 15, 2026 | Dube Eric M | CHIEF EXECUTIVE OFFICER | Sell | 3,102 | $63.64 | $197K | 433,156 | — | — |
| Sep 15, 2026 | Dube Eric M | CHIEF EXECUTIVE OFFICER | Sell | 28,796 | $62.66 | $1.8M | 436,258 | — | — |
| Sep 15, 2026 | Dube Eric M | CHIEF EXECUTIVE OFFICER | Sell | 63,498 | $61.99 | $3.9M | 465,054 | — | — |
| Sep 15, 2026 | Heerma Peter | EVP, CHIEF COMMERCIAL OFFICER | Sell | 1,431 | $65.31 | $93K | 117,066 | — | — |
| Sep 15, 2026 | Heerma Peter | EVP, CHIEF COMMERCIAL OFFICER | Sell | 1,400 | $63.65 | $89K | 118,497 | — | — |
| Sep 15, 2026 | Heerma Peter | EVP, CHIEF COMMERCIAL OFFICER | Sell | 27,421 | $62.59 | $1.7M | 119,897 | — | — |
| Sep 15, 2026 | Heerma Peter | EVP, CHIEF COMMERCIAL OFFICER | Sell | 71,938 | $62.05 | $4.5M | 147,318 | — | — |
| Sep 15, 2026 | Calvin Sandra | SVP, CHIEF ACCOUNTING OFFICER | Sell | 300 | $63.66 | $19K | 42,353 | — | — |
| Sep 15, 2026 | Calvin Sandra | SVP, CHIEF ACCOUNTING OFFICER | Sell | 800 | $62.85 | $50K | 42,653 | — | — |
| Sep 15, 2026 | Calvin Sandra | SVP, CHIEF ACCOUNTING OFFICER | Sell | 4,275 | $62.13 | $266K | 43,453 | — | — |
| Sep 15, 2026 | Inrig Jula | EVP, Head of R&D & CMO | Sell | 400 | $65.31 | $26K | 100,491 | — | — |
| Sep 15, 2026 | Inrig Jula | EVP, Head of R&D & CMO | Sell | 1,600 | $63.69 | $102K | 100,891 | — | — |
8-K · 2.02
!! High
Travere Therapeutics, Inc. -- 8-K 2.02: Earnings Results
Aug 4
8-K · 5.02
!!! Very High
Travere Therapeutics, Inc. -- 8-K 5.02: Executive Change
Jul 9
8-K · 5.02
!!! Very High
Travere Therapeutics, Inc. -- 8-K 5.02: Executive Change
Jun 16
8-K
Travere Therapeutics, Inc. -- 8-K Filing
Jun 2
8-K · 2.02
!! High
Travere Therapeutics, Inc. -- 8-K 2.02: Earnings Results
Travere Therapeutics reported earnings results, with detailed financial performance metrics available in the attached press release exhibit for investor review.
May 4
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
TVTX's FILSPARI demonstrated superior efficacy in reducing proteinuria (48% vs 27%) in IgA nephropathy patients, validating its lead program and strengthening approval prospects for this high-value kidney disease indication.
Apr 14
8-K
Travere Therapeutics, Inc. -- 8-K Filing
Travere Therapeutics' FILSPARI achieved $103 million in Q4 2025 net sales with 108% year-over-year growth and 908 new patient starts, demonstrating strong market adoption for this rare disease treatment.
Feb 19
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Blackrock, Inc. | 8,020,663 | $456M | New | Jun 2026 |
| 2 | Janus Henderson Group Plc | 11,419,586 | $339M | New | Mar 2026 |
| 3 | Fmr Llc | 10,967,967 | $326M | Added | Mar 2026 |
| 4 | Vanguard Capital Management Llc | 4,108,694 | $233M | Added | Jun 2026 |
| 5 | Morgan Stanley | 2,831,794 | $108M | Added | Dec 2025 |
| 6 | Renaissance Technologies Llc | 1,833,079 | $104M | Reduced | Jun 2026 |
| 7 | Emerald Advisers, Llc | 1,600,886 | $91M | New | Jun 2026 |
| 8 | Two Sigma Investments, Lp | 1,565,656 | $89M | Added | Jun 2026 |
| 9 | Vanguard Portfolio Management Llc | 1,541,617 | $88M | Reduced | Jun 2026 |
| 10 | D. E. Shaw & Co., Inc. | 1,440,469 | $82M | Added | Jun 2026 |
| 11 | Nuveen, Llc | 1,054,633 | $60M | Added | Jun 2026 |
| 12 | Emerald Mutual Fund Advisers Trust | 1,032,024 | $59M | New | Jun 2026 |
| 13 | Bank Of America Corp /de/ | 1,345,111 | $40M | Reduced | Mar 2026 |
| 14 | Mpm Bioimpact Llc | 1,133,365 | $34M | New | Mar 2026 |
| 15 | Point72 Asset Management, L.p. | 478,860 | $27M | New | Jun 2026 |
| 16 | Tang Capital Management Llc | 700,000 | $27M | — | Dec 2025 |
| 17 | Ubs Group Ag | 856,757 | $25M | Added | Mar 2026 |
| 18 | Graham Capital Management, L.p. | 446,696 | $25M | New | Jun 2026 |
| 19 | Assenagon Asset Management S.a. | 427,305 | $24M | Added | Jun 2026 |
| 20 | Northern Trust Corp | 781,418 | $23M | Added | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$5.93B
Enterprise Value
$5.78B
P/E (TTM)
—
Forward P/E
217.73x
PEG Ratio
0.79x
P/B
49.53x
P/S
9.62x
P/FCF
150.52x
EV/EBITDA
3740.70x
Shares Out
89.2M
Financials (TTM)
Revenue
$591.3M
Net Income
-$43.5M
EBITDA
$1.5M
Free Cash Flow
$37.8M
Op Cash Flow
$37.8M
EPS Basic
$-0.56
EPS Diluted
$-0.49
EPS Forward
$0.29
Gross Margin
94.4%
Op Margin
-6.8%
Net Margin
-7.3%
Balance Sheet
Total Assets
$605.2M
Total Liab.
$490.4M
Total Equity
$114.8M
Cash
$322.8M
LT Debt
$322.9M
Book Value/Sh
$1.29
Debt/Equity
2.86x
Current Ratio
2.74
Quick Ratio
2.70
Returns & Growth
ROE
-22.2%
ROA
-4.2%
ROIC
-13.9%
Rev Growth YoY
+110.5%
EPS Growth YoY
+86.3%
Price Returns
2W
-3.7%
1M
+1.3%
3M
+17.4%
6M
+140.1%
12M
+167.6%
Technicals
52W High
$68.73
52W Low
$22.05
50d MA
$61.50
200d MA
$43.61
RSI (14)
41.30
ATR (14)
$2.40
Beta
0.87
Avg Volume
1.4M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$51.50
High
$54.00
Low
$49.00
Median
$51.50
Data updated apr 27, 2026 6:09am
· Source: financialmodelingprep.com